Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01GBY
|
||||
| Former ID |
DAP000331
|
||||
| Drug Name |
Desloratadine
|
||||
| Synonyms |
Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] | Approved | [1], [2] | ||
| Therapeutic Class |
Antiallergic Agents
|
||||
| Company |
Schering-Plough
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H19ClN2
|
||||
| InChI |
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
|
||||
| InChIKey |
JAUOIFJMECXRGI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 100643-71-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
515991, 4480883, 10240975, 11528904, 12013632, 14742700, 14874264, 17397787, 25623633, 26719697, 26754458, 29215232, 29215233, 29304216, 46386563, 46507996, 49830094, 50086379, 53790902, 57340751, 75986670, 85209723, 85483828, 87561219, 92307949, 92308612, 92309042, 92712182, 93619677, 103341726, 103966640, 104420034, 104829344, 117782347, 124659138, 125325449, 125336452, 126584136, 126630167, 126656876, 126670272, 126728408, 128248166, 134337643, 134358654, 135078453, 135916143, 137001891, 142370109, 144076154
|
||||
| SuperDrug ATC ID |
R06AX27
|
||||
| SuperDrug CAS ID |
cas=100643718
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H1 receptor | Target Info | Antagonist | [3], [4] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Histamine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther. 2007 Sep;29(9):1795-802. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7157). | ||||
| REF 3 | Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. | ||||
| REF 4 | Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. doi: 10.2165/00002018-200932020-00009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.